This bill tackles a common practice where drug companies get multiple patents on the same medication to extend their monopoly and keep generic versions off the market longer. Here's how it works: if a pharmaceutical company lists several patents as protecting one drug, they now have to prove that each patent actually covers something different. If they can't prove that in court or when generic drug makers challenge them, the company loses patent protection on all those patents once the first one expires. This applies to any legal battle about drug patents, including when generic drug manufacturers try to get FDA approval for cheaper versions.

The bill also tells the U.S. Patent and Trademark Office to tighten up how it reviews drug patents in the first place. Instead of rubber-stamping multiple patents for the same medication, the office needs to make sure each patent genuinely covers a distinct invention before approving it. The goal is straightforward: stop pharmaceutical companies from gaming the patent system to artificially extend their exclusive rights to sell a drug at high prices, which would help generic and biosimilar drugs reach patients faster and at lower costs.

Stopping Pharma’s Ripoffs and Drug Savings For All Act

Ryan, Patrick

Stopping Pharma’s Ripoffs and Drug Savings For All ActThis bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner&nbsp;lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner&nbsp;shall have disclaimed patent protection from all the listed patents after the first patent expires.This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.